The investigators aim to assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test, to exclude CVT in patients with clinical suspicion of CVT.

Consecutive patients with clinical suspicion of CVT at the emergency department of the University Hospital (tertiary care clinic)

Criteria

Inclusion Criteria:

Adults with clinical suspicion of CVT

solated unexplained headache of less than 30 days duration

Headache associated with focal central neurological deficits of less than 30 days duration

Headache associated with disturbed consciousness of less than 30 days duration

Headache associated with epileptic seizures of less than 30 days duration

Unexplained papilledema of less than 30 days duration

Exclusion Criteria

Deep venous thrombosis within 3 months prior to admission

Pulmonary embolism within 3 months prior to admission

Ischemic stroke within 3 months prior to admission

Myocardial infarction within 3 months prior to admission

Other vascular disease within 3 months prior to admission

Headache due to trauma

Malignant neoplasia

Treatment with anticoagulants prior to admission

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00924859